CARY, N.C., January 24, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Syndax Pharmaceuticals as a limited specialty pharmacy provider for REVUFORJTM (revumenib) for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
REVUFORJ, approved by the U.S. Food and Drug Administration (FDA) on November 15, 2024, is a first-in-class targeted therapy and classified as a menin inhibitor, a type of therapy that is paving the way for more effective treatments for the most challenging forms of leukemia. AML and ALL, rapidly progressing cancers of the blood and bone marrow, have long posed a formidable challenge to medical professionals due to its aggressive nature and poor prognosis. REVUFORJ, a drug that targets the menin protein, provides a targeted approach that allows for greater precision in attacking cancer cells while minimizing damage to healthy cells.
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For the full prescribing information for REVUFORJ, please click here. For more information about the treatment of patients with acute myeloid leukemia or acute lymphoblastic leukemia, please click here.